Sawai Eyes Global Position Helped by Japan Growth And Upsher-Smith – But No Biosimilars
Executive Summary
In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.
You may also be interested in...
Catch It While You Can: Smaller Firms Flock To China As Value Takes Center Stage
Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.